Ophthalmology week in review

Here are some recent top articles on
FDA accepts NDA for loteprednol etabonate ophthalmic gel 0.38%
A new drug application for Bausch + Lomb’s sub-micron loteprednol etabonate ophthalmic gel 0.38% has been accepted by the FDA. Read more.
FDA clears Alleye AMD monitoring application
Alleye is designed to detect and monitor age-related macular degeneration and characterize central and paracentral metamorphopsia. Read more.
Women in Ophthalmology Summer Symposium to focus on scientific innovations, burnout and leadership skills
The Women in Ophthalmology 2018
Back to top button